Opinion: Gilead must be held accountable for the harm caused by ‘patent hopping’ an HIV treatment
Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June…
Category: Gilead Sciences
STAT+: Gilead wins U.S. approval for drug to treat autoimmune liver disease
The Food and Drug Administration on Wednesday approved a new treatment for primary biliary cholangitis,…
STAT+: A pricey Gilead HIV drug could be made for dramatically less than the company claims, researchers say
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a…
STAT+: Gilead’s chief medical officer to leave as R&D efforts stall
Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker…
STAT+: Biden administration appeals jury finding in battle over patents for HIV prevention pills
The Biden administration has appealed a decision in which a federal court jury last year…
STAT+: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial
Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected…
STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious…
Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan
A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan…
Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking
Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next…
Listen: The plight of the VC, Gilead’s latest setback, & more M&A
Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to…
No pain data yet from Vertex, and sky high deal expectations at JPM 2024
Want to stay on top of the science and politics driving biotech today? Sign up to…